Delivery of Genome Editing Tools: A Promising Strategy for Hpv-Related Cervical Malignancy Therapy Publisher Pubmed



Aghamiri S^{1, 2} ; Talaei S³ ; Roshanzamiri S⁴ ; Zandsalimi F⁵ ; Fazeli E⁶ ; Aliyu M⁷ ; Kheiry Avarvand O⁸ ; Ebrahimi Z⁹ ; Keshavarzfathi M^{10, 11} ; Ghanbarian H^{2, 9, 12}
Source: Expert Opinion on Drug Delivery Published:2020

Abstract

Introduction: Persistent high-risk human papillomavirus infection is the main cause of various types of cancer especially cervical cancer. The E6 and E7 oncoproteins of HPV play critical roles in promoting carcinogenesis and cancer cell growth. As a result, E6 and E7 oncogenes are considered as promising therapeutic targets for cervical cancer. Recently, the development of genome-editing technologies including transcription activator-like effector nucleases (TALEN), meganucleases (MNs), zinc finger nucleases (ZFN), and more importantly clustered regularly interspaced short palindromic repeat-CRISPR-associated protein (CRISPR-Cas) has sparked a revolution in the cervical cancer-targeted therapy. However, due to immunogenicity, off-target effect, renal clearance, guide RNA (gRNA) nuclease degradation, and difficult direct transportation into the cytoplasm and nucleus, the safe and effective delivery is considered as the Achilles’ heel of this robust strategy. Areas covered: In this review, we discuss cutting-edge available strategies for in vivo delivery of genome-editing technologies for HPV-induced cervical cancer therapy. Moreover, the combination of genome-editing tools and other therapies has been fully discussed. Expert opinion: The combination of nanoparticle-based delivery systems and genome-editing tools is a promising powerful strategy for cervical cancer therapy. The most significant limitations of this strategy that need to be focused on are low efficiency and off-target events. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.